Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer's Drug Development

Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune Bio" or the "Company"), a clinical-stage inflammation and immunology company, today announced that Malú Gámez Tansey, Ph.D., Professor of Neurology at the Stark Neuroscience Research Institute at Indiana University School of Medicine, will feature the Company's Phase 2 MINDFuL trial of XPro™ (pegipanermin) as a centerpiece of her plenary presentation at AD/PD 2026 — the world's leading international conference on Alzheimer's and Parkinson's diseases — taking place March 17–21, 2026 in Copenhagen, Denmark.